Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 3Thoracic 1Sarcoma 1Other solid neoplasm 1Other neoplasm 1Other hematologic neoplasm 1Lymphoid 1Gynecologic 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Osteosarcoma 1Melanoma 1Lymphoma 1Endocrine Gland Neoplasms 1

Interventions

Cyclophosphamide 342Rituximab 304Vincristine 157Doxorubicin 154venetoclax 153fludarabine 153Specimen Handling 152Prednisone 150Biopsy 122Magnetic Resonance Spectroscopy 117obinutuzumab 116Lenalidomide 109Dexamethasone 104Cytarabine 97ibrutinib 95Etoposide 92fludarabine phosphate 87Methotrexate 84acalabrutinib 78Bendamustine Hydrochloride 72zanubrutinib 71blinatumomab 63pembrolizumab 62CT-P10 60Gemcitabine 51Nivolumab 45glofitamab 44Calcium Dobesilate 44Mercaptopurine 43prednylidene 42

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Psilocybin × Lymphoid × 1 year × Clear all
NCT06416085 2026-03-05

Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) Therapy for Patients With Advanced Cancer

University Health Network, Toronto

Phase 2 Active not recruiting
15 enrolled
DermatologicLymphoidSarcoma

Endocrine Gland Neoplasms, Lymphoma, Melanoma, Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡